Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options.

Area of Science:

• Rheumatology
• Geriatric Medicine
• Clinical Immunology

Background:

• Elderly-onset rheumatoid arthritis (EORA), defined as rheumatoid arthritis (RA) onset after age 60, presents distinct clinical and immunological features.
• EORA is characterized by acute onset, constitutional symptoms, systemic manifestations, large joint involvement, elevated inflammatory markers, and increased patient disability.
• RA comprises overlapping subsets, including classical RA, polymyalgia rheumatica-like phenotype, and remitting seronegative symmetrical synovitis with pitting edema syndrome.

Purpose of the Study:

• To highlight the unique clinical profile of EORA.
• To emphasize the challenges and contraindications of non-steroidal anti-inflammatory drug (NSAID) use in elderly patients.
• To advocate for the immediate initiation of disease-modifying antirheumatic drugs (DMARDs) in EORA management.

Main Methods:

• Review of clinical features and treatment considerations for EORA.
• Analysis of NSAID safety concerns and contraindications in the elderly population.
• Evaluation of DMARD therapy, including conventional, biological, and targeted synthetic options, for EORA.

Main Results:

• NSAIDs are generally not first-line treatment for EORA due to significant side effect risks and comorbidities in seniors.
• DMARDs, particularly methotrexate, are recommended immediately upon EORA diagnosis.
• Biological or targeted synthetic DMARDs are effective for elderly patients resistant to conventional DMARDs.

Conclusions:

• EORA necessitates tailored treatment strategies, prioritizing DMARDs over NSAIDs.
• Future research should focus on personalized DMARD approaches considering disease activity, comorbidities, and safety.
• Optimizing EORA treatment aims to improve outcomes, reduce glucocorticoid reliance, and enhance patient quality of life.